Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancerMaximilian Marhold, Rupert Bartsch, Muna Ferner et al.|OncoImmunology|2023Cited by 30
187P Stage I results of a phase II study of datopotamab deruxtecan (DATO-DXd) in triple-negative breast cancer (TNBC) patients (pts) with active brain metastases (TUXEDO-2)Rupert Bartsch, Matthias Preusser, Anna S. Berghoff et al.|ESMO Open|2024Cited by 15